Corvus Pharmaceuticals, Inc.   Report issue

For profit Phase 1 Phase 3
Founded: Burlingame CA United States (2014)

Organization Overview

First Clinical Trial
2016
NCT02655822
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Corvus Pharmaceuticals | Corvus Pharmaceuticals, Inc.

Active Ingredients

Drugs in Phase 3 Trials (1)

cpi-006 (3 trials)

Drugs in Phase 1 Trials (5)

atezolizumab (Tecentriq) (1 trial)

ciforadenant (4 trials)

cpi-818 (1 trial)

daratumumab (darzalex) (1 trial)

pembrolizumab (keytruda) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Renal Cell (Phase 1)

Endometrial Neoplasms (Phase 1)

Lymphoma (Phase 1)

Lymphoma, T-Cell (Phase 1)

Multiple Myeloma (Phase 1)

Neoplasms, Plasma Cell (Phase 1)

Prostatic Neoplasms (Phase 1)

Sarcoma (Phase 1)

Squamous Cell Carcinoma of Head and Neck (Phase 1)

Triple Negative Breast Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 7
  • # of Trial APIs: 6